Drug Profile

Veliparib - Abbvie

Alternative Names: ABT-888; NSC-737664

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abbott Laboratories
Developer Abbott Laboratories; AbbVie
Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Phase II/III Glioblastoma
Phase II Brain metastases; Breast cancer; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
Phase I/II Glioma; Head and neck cancer; Prostate cancer; Small cell lung cancer
No development reported Leukaemia; Lymphoma; Multiple myeloma
Discontinued Liver cancer

28 Dec 2025 No recent reports of development identified for phase-I development in Leukaemia(Combination therapy) in USA (PO, Pill)
12 Jun 2025 Pharmacodynamics data from a preclinical studies in Multiple myeloma presented at the 30^th Congress of the European Haematology Association (EHA-2025)
28 May 2025 Pharmacokinetics data from preclinical trial presented at the 126^th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com